Study guide

15.3 Breast Staging (AJCC 8th Edition, Part XI): T, N, M, Anatomic & Prognostic Stage Groups

NCRA Oncology Data Specialist ODS-C

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The ODS-C Exam, the Oncology Data Specialist Profession & Standard Setters

1.1 ODS Exam Structure, Timing, Scoring & 2026 Testing Windows 1.2 From CTR to ODS: The Credential, Eligibility Routes & the Registrar's Role 1.3 Standard-Setting Organizations & the Manuals They Publish

2 Chapter 2: Legal Framework, HIPAA & State Reporting Laws

2.1 HIPAA Privacy Rule & the Public Health Reporting Exception 2.2 HIPAA Security Rule, Safeguards & Breach Notification 2.3 State Mandatory Cancer Reporting Laws & Statutory Authority

3 Chapter 3: Confidentiality, Release of Information, Ethics & Credential Maintenance

3.1 Patient Confidentiality Protocols & Data Access Policies 3.2 Handling Subpoenas, Discovery & Registry Immunity Statutes 3.3 NCRA Code of Ethics & ODS Credential Maintenance

4 Chapter 4: Registry Organization, Staffing & Information Systems

4.1 Types of Cancer Registries, Their Functions & Registry Operating Protocols 4.2 Registry Staffing Formulas, Time Studies & Resource Allocation 4.3 Electronic Registry Systems, Security & Disaster Recovery Planning

5 Chapter 5: Cancer Committee, Cancer Conferences & Quality Improvement

5.1 The Cancer Committee: CoC Standards 2.1–2.4, the CLP & Annual Program Activities 5.2 Multidisciplinary Cancer Case Conferences (CoC Standard 2.5) 5.3 Quality Improvement Principles & CoC Chapter 7 (Standards 7.1–7.3)

6 Chapter 6: CoC Accreditation Standards, NCDB & Data Quality

6.1 CoC Accreditation: Standards Structure, Program Categories & Accreditation Awards 6.2 The National Cancer Database (NCDB), RCRS Submission & CoC Quality Measures 6.3 Quality Control Plans & Audit Techniques (CoC Standard 6.1)

7 Chapter 7: Surveillance Programs, NAACCR Standards, Epidemiology & Statistics

7.1 National Cancer Surveillance Programs: SEER & CDC NPCR 7.2 NAACCR Data Exchange Standards, XML Data Specifications & Registry Certification 7.3 Basic Cancer Epidemiology & Descriptive Statistics 7.4 Basic Statistics: Frequency Distributions, Central Tendency, Risk Ratios & Odds Ratios 7.5 Survival Analysis, Life Tables & Presentation of Registry Data

8 Chapter 8: Medical Terminology, Anatomy & Types of Cancer

8.1 Medical Terminology & Standard Abbreviations for Cancer Abstracting 8.2 Human Anatomy & Physiology for Registrars: Tissues, Organ Walls, Subsites & Lymphatic Drainage 8.3 Types & Characteristics of Cancer: Benign vs. Malignant, Tumor Families, Spread & Precursors

9 Chapter 9: Casefinding & Reportability

9.1 Principles of Casefinding & Facility Reference Dates 9.2 Casefinding Sources: Pathology, Cytology, Disease Index & Logs 9.3 Reportability: What CoC, SEER and NPCR Require, Including Non-Malignant CNS Tumors 9.4 Ambiguous Terminology: Reportable Terms, Cytology, Discrepancies & "References of Last Resort"

10 Chapter 10: Diagnostic Procedures, Pathology Reporting, Lab Methods & Prognostic Indicators

10.1 Diagnostic & Staging Procedures: Imaging, Endoscopy, Biopsy & How They Are Coded 10.2 Pathology Reporting, CAP Cancer Protocols & Electronic Pathology (CoC Standard 5.1) 10.3 Specialty Laboratory Testing Methods: IHC, FISH, PCR/RT-PCR, NGS, Flow Cytometry & Cytogenetics 10.4 Prognostic Indicators & Site-Specific Data Items (SSDIs): HPV, KRAS, HER2 and More

11 Chapter 11: Class of Case, Key Dates & Case Identifiers

11.1 Class of Case, Date of First Contact, Date of Diagnosis & Accession/Sequence Numbers 11.2 Analytic Classes of Case (00, 10–14, 20–22): Definitions & Decision Rules 11.3 Nonanalytic Classes of Case (30–49, 99) & Why Central Registries Need Them

12 Chapter 12: Follow-Up, Vital Status & Recurrence

12.1 Follow-Up Purpose, Active & Passive Methods, and Follow-Up Source Codes 12.2 CoC Standard 6.5 Follow-Up Rates: Windows, Exclusions & Calculations 12.3 Vital Status, Date of Last Contact, Cancer Status & Death Clearance 12.4 Recurrence: Type of First Recurrence [1880], Date of First Recurrence [1860] & Recurrence vs. New Primary

13 Chapter 13: Abstracting, ICD-O-3.2 Site & Histology Coding, and Grade

13.1 The Abstracting Process: Workflow, Source Documents, Timeliness & Text Documentation 13.2 ICD-O-3.2 Topography, Primary Site Rules & Laterality 13.3 ICD-O-3.2 Morphology: Histology, Behavior & the Solid Tumor Histology Rules 13.4 Grade: The Four Time-Specific Grade Items & Site-Specific Grade Tables

14 Chapter 14: Solid Tumor Rules & Hematopoietic Coding Rules

14.1 Solid Tumor Rules: Purpose, Site Groups, Navigation & Timing Principles 14.2 Solid Tumor Rules for Breast, Colon/Rectum & Lung: The Multiple Primary Rules in Order 14.3 Solid Tumor Rules for Head & Neck, Kidney, Urinary, CNS, Melanoma & Other Sites 14.4 Hematopoietic & Lymphoid Neoplasms: Heme Manual, Heme DB, Multiple Primary & Primary Site Rules

15 Chapter 15: Staging: AJCC TNM (8th Edition & Version 9 Lung) and Summary Stage 2018

15.1 AJCC TNM Principles: Categories, Prefixes, Suffixes, General Rules & Registry Items 15.2 AJCC Time Frames: Clinical, Pathological, Post-Therapy (yc, yp), Recurrence & Autopsy 15.3 Breast Staging (AJCC 8th Edition, Part XI): T, N, M, Anatomic & Prognostic Stage Groups 15.4 Lung Staging (AJCC Version 9, 2025+): T, N2a/N2b, M1c1/M1c2 & New Stage Groups 15.5 Male Genital & Urinary Tract Staging (AJCC 8th Parts XIII–XIV): Prostate, Testis, Kidney, Bladder, Renal Pelvis & Ureter 15.6 SEER Summary Stage 2018: Codes, Timing, General Rules & Site Examples

16 Chapter 16: First-Course Treatment Coding (STORE 2025) & EDITS

16.1 Treatment Types, First Course of Treatment & Evidence-Based Guidelines (NCCN) 16.2 Surgery Coding: Rx Summ–Surg 2023 [1291], Lymph Node Surgery [1292], Other Site [1294], Margins & Reason for No Surgery 16.3 Radiation, Systemic, Transplant, Other & Palliative Treatment Coding (STORE 2025) 16.4 NAACCR EDITS, Over-ride Flags & Data Validation

15.3 Breast Staging (AJCC 8th Edition, Part XI): T, N, M, Anatomic & Prognostic Stage Groups

Key Takeaways Explain This Topic AI

Breast T is based on the size of the largest invasive focus: T1mi 1 mm or less, T1a more than 1–5 mm, T1b more than 5–10 mm, T1c more than 10–20 mm, T2 more than 20–50 mm, and T3 more than 50 mm; tumors between 1 and 2 mm are rounded up to 2 mm.

T4 requires chest wall invasion (not pectoralis muscle alone), skin ulceration, macroscopic satellite skin nodules or edema including peau d'orange (T4b), both (T4c), or inflammatory carcinoma (T4d); dermal invasion alone is not T4.

LCIS was removed from the 8th edition T categories; Tis is DCIS or Paget disease without an underlying invasive or in situ tumor.

Isolated tumor cells (0.2 mm or less, or 200 cells or fewer) are pN0(i+), micrometastases (more than 0.2 mm to 2 mm) are pN1mi, and pN1a to pN3a count axillary nodes as 1–3, 4–9, and 10 or more.

U.S. registries record the prognostic stage groups, which add grade, ER, PR and HER2; a 21-gene recurrence score below 11 places T1–T2 N0 M0, ER-positive, HER2-negative tumors in pathological prognostic stage IA.

Last updated: September 2026

Primary tumor (T)

  • T Definition
  • TX Primary tumor cannot be assessed
  • T0 No evidence of primary tumor
  • Tis (DCIS) Ductal carcinoma in situ

Tis (Paget) Paget disease of the nipple not associated with invasive carcinoma or DCIS in the underlying parenchyma

  • T1mi Invasive tumor 1 mm or less
  • T1a More than 1 mm to 5 mm
  • T1b More than 5 mm to 10 mm
  • T1c More than 10 mm to 20 mm
  • T2 More than 20 mm to 50 mm
  • T3 More than 50 mm

T4a Extension to the chest wall (ribs, intercostal muscles, serratus anterior). Invasion of the pectoralis muscle alone is not T4

T4b Skin ulceration , ipsilateral macroscopic satellite nodules , or skin edema (including peau d'orange) that does not meet inflammatory criteria

  • T4c Both T4a and T4b
  • T4d Inflammatory carcinoma
  • T rules

Measure the invasive component only. The DCIS portion does not add to T size.

Rounding: round to the nearest millimeter. A tumor more than 1 mm but less than 2 mm is rounded up to 2 mm , so T1mi is only for 1.0 mm or less.

Multiple tumors: T is based on the largest tumor, with the (m) suffix. Sizes of separate tumors are not added together.

Dermal invasion alone , or skin dimpling or nipple retraction, does not make a tumor T4b. Ulceration, satellite nodules or edema are required.

Inflammatory carcinoma (T4d) is a clinical diagnosis: diffuse erythema and edema involving a third or more of the breast skin . Tumor in dermal lymphatics without the clinical findings is not T4d.

Paget disease with an underlying tumor is staged by the underlying tumor.

LCIS is treated as a benign entity and was removed from the Tis categories in the 8th edition.

Regional lymph nodes (N)

Regional nodes: ipsilateral axillary nodes (levels I, II and III, including interpectoral or Rotter's nodes), ipsilateral internal mammary nodes, and ipsilateral supraclavicular nodes. Contralateral nodes and cervical nodes are distant (M1) . Intramammary nodes are coded as axillary nodes.

Clinical N (cN)

  • cN Definition
  • cN1 Movable ipsilateral level I or II axillary nodes
  • cN2a Fixed or matted ipsilateral level I or II axillary nodes
  • cN2b Ipsilateral internal mammary nodes without axillary nodes
  • cN3a Ipsilateral infraclavicular (level III) nodes
  • cN3b Ipsilateral internal mammary and axillary nodes
  • cN3c Ipsilateral supraclavicular nodes
  • Pathological N (pN)
  • pN Definition
  • pN0(i+) Only isolated tumor cells (0.2 mm or less, or 200 cells or fewer)
  • pN1mi Micrometastases : more than 0.2 mm (or more than 200 cells) but none larger than 2.0 mm
  • pN1a 1–3 axillary nodes, at least one metastasis larger than 2.0 mm
  • pN1b Ipsilateral internal mammary sentinel nodes, excluding ITCs
  • pN1c pN1a plus pN1b
  • pN2a 4–9 axillary nodes, at least one larger than 2.0 mm
  • pN2b Clinically detected internal mammary nodes, with pathologically negative axillary nodes
  • pN3a 10 or more axillary nodes, or infraclavicular (level III) nodes
  • pN3b pN1a or pN2a with cN2b (imaging-positive internal mammary nodes), or pN2a with pN1b
  • pN3c Ipsilateral supraclavicular nodes

Node rules:

Only nodes with metastases larger than 0.2 mm count toward the number of positive nodes. STORE applies the same rule to Regional Nodes Positive [820] : nodes with only ITCs are not counted as positive for any site except cutaneous melanoma and Merkel cell carcinoma. If the size of a nodal metastasis is not stated, assume it is larger than 0.2 mm.

The (sn) suffix applies when only sentinel nodes were examined. The breast chapter drops (sn) when six or more sentinel nodes are removed.

Distant metastasis (M)

  • M Definition
  • cM0 No clinical or imaging evidence

cM0(i+) No clinical or imaging evidence, but tumor cells or deposits 0.2 mm or smaller found in blood, bone marrow or other non-regional tissue, without symptoms

  • cM1 Distant metastasis by clinical or imaging means
  • pM1 Histologically proven metastasis larger than 0.2 mm , or in non-regional nodes
  • Anatomic stage groups
  • Stage T N M
  • 0 Tis N0 M0
  • IA T1 N0 M0
  • IB T0–T1 N1mi M0
  • IIA T0–T1 N1 M0
  • IIA T2 N0 M0
  • IIB T2 N1 M0
  • IIB T3 N0 M0
  • IIIA T0–T3 N2 M0
  • IIIA T3 N1 M0
  • IIIB T4 N0–N2 M0
  • IIIC Any T N3 M0
  • IV Any T Any N M1
  • Prognostic stage groups

The 8th edition added Clinical Prognostic Stage (for all patients) and Pathological Prognostic Stage (for patients whose first treatment is surgery). They combine anatomic TNM with grade, HER2, ER and PR . In the United States, these prognostic stage groups are used for patient care and registry reporting. The anatomic table is for regions where biomarker testing is not available.

21-gene recurrence score: for T1–T2, N0, M0, ER-positive, HER2-negative tumors, a score below 11 puts the pathological prognostic stage at IA , whatever the grade or PR status.

Missing biomarkers can prevent a valid prognostic stage group. In STORE, a stage group that cannot be determined is coded 99 .

Tumors that are ER-, PR- and HER2-negative (triple negative) tend to move to a higher prognostic stage than their anatomic stage. Low-grade, ER-positive, HER2-positive tumors tend to move lower .

Post-neoadjuvant (yp) notes

ypT is based on the largest contiguous focus of residual invasive tumor. Treatment-related fibrosis is excluded.

ypN uses the same size thresholds. Nodes with treatment effect but no residual tumor are negative.

A patient who was M1 before therapy stays stage IV after therapy.

Worked examples

A 1.6 cm invasive carcinoma NST, 0 of 3 sentinel nodes, no clinical evidence of metastasis, is resected first. That gives pT1c pN0(sn) cM0 , anatomic stage IA , and a prognostic stage that depends on grade, ER, PR and HER2.

A 3.5 cm tumor with 4 of 14 axillary nodes positive (largest deposit 6 mm) gives pT2 pN2a cM0 , anatomic stage IIIA .

Peau d'orange over the lower half of the breast, a 2 cm underlying mass, and no diffuse erythema gives cT4b , not T4d, because inflammatory carcinoma needs its clinical criteria.

Loading diagram... Breast pathological N by number and size